
mRNA Vax Scores Big! Cancer Risk Slashed in New Trial
Big news for cancer treatment! Moderna and Merck's personalized mRNA vaccine is showing serious promise, slashing the risk of recurrence and death in high-risk skin cancer patients by nearly 50% over five years, potentially revolutionizing how we fight this disease. With Phase 3 trials underway, this innovative approach could be a game-changer, offering hope and a new lease on life for countless individuals.

























